Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4171 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, GeneReach Biotechnology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneReach Biotechnology FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GeneReach Biotechnology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where GeneReach Biotechnology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneReach Biotechnology (ROCO:4171) has a FCF Margin % of 10.33% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on GeneReach Biotechnology and its competitors. According to the industry distribution chart, GeneReach Biotechnology ranks #307 out of 950 companies in the Biotechnology industry, placing it in the top 32.3%.
Is GeneReach Biotechnology's FCF Margin % too high?
GeneReach Biotechnology's current FCF Margin % is 10.33%. Based on the distribution chart, GeneReach Biotechnology ranks #307 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GeneReach Biotechnology has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneReach Biotechnology's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GeneReach Biotechnology ranks #307 out of 950 companies for FCF Margin %. This puts GeneReach Biotechnology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on GeneReach Biotechnology and its competitors. GeneReach Biotechnology's current FCF Margin % is 10.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneReach Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, GeneReach Biotechnology (ROCO:4171) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$23.99, compared to a current price of NT$18.45 — trading 23.1% below its estimated fair value. The current FCF Margin % is 10.33%. GeneReach Biotechnology's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For GeneReach Biotechnology (ROCO:4171), the current FCF Margin % is 10.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneReach Biotechnology (ROCO:4171) Overvalued in 2026?
Based on GuruFocus' analysis, GeneReach Biotechnology stock appears to be undervalued.
The current stock price of NT$18.45 is trading 23.1% below its estimated GF Value™ of NT$23.99.
GuruFocus considers GeneReach Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:4171:
FCF Margin %: 10.33%
GF Value™: NT$23.99 vs. price of NT$18.45 (23.1% below fair value)
No single metric tells the full story. See the ROCO:4171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneReach Biotechnology Corp is a biotechnology company. The company develops, manufactures and markets products for applied nucleic acid detection technology. Its products are utilised for aquaculture, agriculture, food, companion animal, livestock and human health industries.
60GF Score
Get the complete analysis for ROCO:4171
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4171 has been successfully added to your 
